SHPGY (SHIRE PLC ADS)

Zecco.com
All Pro Portfolios with SHPGY

People owning SHPGY also tend to own:: ALCEGCMXDAVEKBMINDMIR

All Do-It-Yourself Portfolios with SHPGY
  • News For Selected Stock
  • Related stories on theStreet.com
  • videos related to etf's
  • No videos found
  •  
  • blogs related to etf's
  • No blogs found
  •  

Why I Love This Stock

By:barrons2

Date:06 14 08

Although Shire shares have already dropped, they could fall another 15%-20% if the drug maker can't keep it's grip on the attention-deficit hyperactivity disorder market.

Not yet rated
Rate now:

By:barrons2

Date:05 24 08

Outperform - Price 51.91 on May 21
by Friedman Billings Ramsey

We continue to believe SHPGY is unique among branded specialty-pharma companies with limited generic exposure following the erosion of Adderall XR in 2009. Shares are trading at 17 times the 2009 Street EPS estimate of $3.12. This translates into a P/E-to-growth rate of 0.9 times, with an estimated EPS CAGR [compound annual growth rate] of 18% for 2009-'13 (the group trades nearer 1.5). Maintaining Outperform, 75 target. Market cap: $9.6 billion.

Not yet rated
Rate now:

By:barrons2

Date:10 06 07

Outperform - Price 75.25 on Oct. 3
by Cowen & Co.
Recent physician checks indicate high satisfaction in efficacy and tolerability of Vyvanse [for attention-deficit/hyperactivity disorder]. It appears most clinicians aren't moving well-controlled Adderall XR patients to Vyvanse but new patient-start commentary for Vyvanse remains favorable. Rarely do we find a firm with [a] new product cycle with extended intellectual-property protection combined with a development pipeline that should provide extended sustainable growth...'06 EPS was $1.71; '07 estimated, $2.05; '08E, $2.75; '09E $3.10.

Not yet rated
Rate now:

By:barrons2

Date:10 06 07

Outperform - Price 75.25 on Oct. 3
by Cowen & Co.
Recent physician checks indicate high satisfaction in efficacy and tolerability of Vyvanse [for attention-deficit/hyperactivity disorder]. It appears most clinicians aren't moving well-controlled Adderall XR patients to Vyvanse but new patient-start commentary for Vyvanse remains favorable. Rarely do we find a firm with [a] new product cycle with extended intellectual-property protection combined with a development pipeline that should provide extended sustainable growth...'06 EPS was $1.71; '07 estimated, $2.05; '08E, $2.75; '09E $3.10.

Not yet rated
Rate now:

By:anur0

Date:09 28 07

Few co's with this kind of pipeline. Stock trades on Vyvance scrpts data now. So be careful and buy on a pullback; but this one will be 105 in 1 year.

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

Downgraded by JP Morgan from Overweight to Neutral

Not yet rated
Rate now:

By:mikeluptak

Date:06 13 07

Good potential for private health care in England.

Not yet rated
Rate now:

By:gomp32

Date:06 02 07

Looks Good

Not yet rated
Rate now:

By:supratrade

Date:04 05 07

Ratings change: buy, Price target: USD 75

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

Downgraded by Jefferies & Co from Hold to Buy

Not yet rated
Rate now:

Why I Hate This Stock

Comments not available
Add Your Comments  
Stock SHPGY
Allowed HTML tags: <a><b><i><img>
  Login to post your comments
Top Biotech Short-Squeeze Plays

One industry that is expected to do well in a Barack Obama presidency is biotech. With the drop in the stock market bringing down all stocks, including the biotechs, short-...

11.20.08 | 18:30 PM
Cramer's Take on Top-Searched St...

As if Wednesday's blood bath wasn't enough, Wall Street was further rattled on Thursday after the Labor Department reported that new claims for unemployment benefits climbe...

11.20.08 | 17:59 PM
Jim Cramer's Portfolios of the Week

Jim Cramer has no problem with remaining in the bear camp on Wall Street. Recently, he spotted a new crisis on the horizon for the commercial real estate market, and on Thu...

11.20.08 | 17:11 PM
Approach China Medical With Caution

Financial research is never a simple task. It requires a substantial time commitment to read over a company's recent filings and listen to its investor presentation, as we...

11.20.08 | 14:15 PM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZackAttack
Free XXX porn and sex FREE video
11.21.08 | 22:49 PM From author Lezearresty
Rothschild Investment Banking Po...
11.21.08 | 21:16 PM From author surfsk8sno
Cabinet Members
11.21.08 | 17:26 PM From author MTnews
more forums
today 's lists
Stocks Most Likely to Surprise

This list consists of stocks that are down 10% or more in the last year but may be poised to surprise us on the upside going forward. The basis for the list is as follows: ... more

Rising on Unusual Volume

Every day after the close we will list the top stocks rising on unusual volume that trading day. Nov. 20, 2008. more

Large Cap Value Plays

This is a screen of large cap stocks, i.e. with market capitalizations greater than or equal to $5 billion that also have a P/E less than or equal to 15 and a quick ratio o... more